CORONAVIRUS

Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice

Andrew C. Hunt1,2†, James Brett Case3†, Young-Jun Park4†, Longxing Cao5,7†, Kejia Wu4,7, Alexandra C. Walls5,6†, Zhuming Liu1,7, John E. Bowen4, Hsien-Wei Yeh4,5, Shally Saini4,5, Louisa Helms8,9,10,24, Yan Ting Zhao4,5,11, Tien-Ying Hsiang5, Tyler N. Starr3, Inna Goreshnik4,5, Lisa Kozodoy4,5, Lauren Carter4,5, Rashmi Ravichandran4,5, Lydia B. Green4, Wadim L. Matchoiko4, Christy A. Thomson12, Bastian Vogeli2,15, Antje Krüger3,2, Laura A. VanBlargan3, Rita E. Chen3,16, Baoling Ying3, Adam L. Bailey16,17, Natasha M. Kafai3,16, Scott E. Boyken4,5, Ajasja Mary Jane Navarro4, Nuttada Panpradist23, Michael Gale Jr.12, Benjamin S. Freedman8,9,10,23,24, Jesse D. Bloom10,8,25, Hanneke Ruohola-Baker4,6,11,12,13†, Sean P. J. Whelan8, Lance Stewart4,5, Michael S. Diamond3,5,7,16,26*, David Veesler4,5,6, Michael C. Jewett1,2,3,7,28*, David Baker4,5,6*.1

1Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, 60208, USA 2Center for Synthetic Biology, Northwestern University, Evanston, IL, 60208, USA 3Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA 4Department of Biochemistry, University of Washington, Seattle, WA, 98195, USA 5Institute for Protein Design, University of Washington, Seattle, WA, 98195, USA 6Howard Hughes Medical Institute, University of Washington, Seattle, WA, 98195, USA 7Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA 8Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, 98195, USA 9Division of Hematology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98195, USA 10Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98195, USA 11Kidney Research Institute, University of Washington School of Medicine, Seattle, WA, 98195, USA 12Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, 63110, USA 13Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA, 98195, USA 14Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA 15Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA, 98195, USA 16Division of Immunology, University of Washington School of Medicine, Seattle, WA, 98195, USA 17Division of Nephrology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98195, USA 18Department for Synthetic Biology and Immunology, National Institute of Chemistry, Ljubljana, SI-1000, Slovenia 19Department of Chemical and Biological Engineering, Northwestern University, Evanston, IL, 60208, USA 20Medical Scientist Training Program, University of Washington, Seattle, WA, 98195, USA 21Department of Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA 22Neulokin Therapeutics Inc., Seattle, WA, 98102, USA 23The Molecular and Cellular Biology Program, University of Washington, Seattle, WA, 98195, USA 24Department of Bioengineering, University of Washington, Seattle, WA, 98195, USA 25Department of Immunology, University of Washington School of Medicine, Seattle, WA, 98195, USA 26Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA 27Department of Pathology & Immunology, University of Washington School of Medicine, St. Louis, MO, 63110, USA 28Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, 60208, USA 29Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, 60611, USA 30These authors contributed equally to this work

†These authors contributed equally to this work

*Corresponding authors: Michael S. Diamond (mdiamond@wustl.edu), David Veesler (dveesler@uw.edu), Michael C. Jewett (m-jewett@northwestern.edu), David Baker (dbaker@uw.edu)

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy with a homo-trimeric version of the 75-residue angiotensin converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. In the cryo-electron microscopy structure, TRI2 formed a tripod on top of the spike protein which engaged all three receptor binding domains (RBDs) simultaneously as in the design model. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than that of monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies and native receptor traps. By comparison, the designed proteins have resistance to viral escape and antigenic drift by construction, precisely tuned avidity, and greatly reduced chance of autoimmune responses.
INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause a global pandemic with more than 300 million infections and 5.5 million deaths as of January 2022 (https://covid19.who.int/). Monoclonal antibodies (mAbs) targeting the SARS-CoV-2 spike (S) glycoprotein (1) have been an effective treatment for improving outcomes for patients with coronavirus disease 2019 (COVID-19) (2–5), but many are sensitive to viral escape through point mutations in their epitopes on the S trimer (6, 7), and producing mAbs in sufficient quantities for population scale use during a global pandemic is technically and financially challenging (8). Indeed, the continued emergence of variants of concern (VOCs) jeopardizes the effectiveness of currently approved mAb treatments and vaccines (9–14). In particular, mutations in the rapidly spreading B.1.1.529 (Omicron) variant disrupt binding of most receptor binding motif-targeted mAbs, and have been shown to reduce neutralization potency more than 100-fold for five of the seven clinical mAbs used for the prophylactic or therapeutic treatment of COVID-19 (15–18). Thus, there is an urgent need for interventions whose efficacy is not disrupted by the observed ongoing antigenic drift, as is the case for a few mAbs (19–24).

As an alternative to mAbs, we previously computationally designed two classes of minibinder proteins that block the SARS-CoV-2 receptor binding domain (RBD) interaction with its host receptor, angiotensin converting enzyme 2 (ACE2) (25). The first class, exemplified by AHB2, adopts a similar binding mode to and incorporates residues from the main RBD-interacting helix of ACE2 in a custom designed 3-helix bundle that has low overall sequence similarity with ACE2. The second class, exemplified by LCB1 and LCB3, contain an bundle that has low overall sequence similarity with ACE2 to infect cells (24, 38). We describe the design, optimization, and escape resistance of both classes of constructs. We find that the top constructs have considerable promise as potential countermeasures in the ongoing COVID-19 pandemic.

RESULTS

RBD mutations impact minibinder binding.

To determine the potential for mutations to arise that disrupt LCB1 and AHB2 binding to the RBD, we performed deep mutational scans using site saturation mutagenesis of the RBD (38). We found that for LCB1, the widely observed K417N mutation results in a greater than 100-fold reduction in affinity (fig. S1). For AHB2, we similarly observed several mutations, including K417N, E406W, and Y453K/R, which reduce the affinity of the minibinder for the RBD.

Multivalent minibinders bind to SARS-CoV-2 RBDs.

To improve the ability of the minibinders to neutralize circulating SARS-CoV-2 variants, we developed multivalent versions with geometries enabling simultaneous engagement of all 3 RBDs in a single S trimer (1) to increase binding avidity. Multivalent minibinders might be less sensitive to mutations that would escape binding of the monovalent minibinders; a 100x reduction in binding affinity of a sub-picomolar binder that would escape binding of the monovalent minibinders; a 100x reduction in binding affinity of a sub-picomolar binder would still result in an affinity in a therapeutic range in a multivalent construct (39). We also hypothesized that constructs with binding domains containing different sets of contacts with the target epitope could prevent escape (32, 37). To design multivalent constructs, we started from optimized versions of the previously described LCB1, AHB2, and LCB3 minibinders (hereafter referred to as monomers MON1, MON2, and MON3, respectively; table S1) (25).

To rapidly prototype multivalent minibinder designs, we developed a cell-free protein synthesis (CFPS) workflow which combines an in vitro DNA assembly step followed by polymerase chain reaction (PCR) to generate linear expression templates that are used to drive CFPS and enable rapid prototyping of new minibinder designs (fig. S2). The workflow enables assembly and translation of synthetic genes and generation of purified protein in as little as 6 hours, is compatible with high-throughput, automated experimentation using an acoustic liquid handler (Echo 525), and is easily

RBD binding avidity; these constructs have the advantages that LCB1 and LCB3 are very high affinity binders on their own, and the three domains contain different sets of contacts with the RBD, making escape in principle more difficult (32, 37). The second consists of self-assembling homotrimers of minibinders geometrically matched to the 3 RBDs on a single spike; although AHB2 is lower affinity than LCB1 and LCB3, and the sites targeted are less diverse than the first class, homotrimers of AHB2 have the advantage that the ACE2 binding site is inherently less mutable as the virus must bind ACE2 to infect cells (24, 38). We describe the design, optimization, and escape resistance of both classes of constructs. We find that the top constructs have considerable promise as potential countermeasures in the ongoing COVID-19 pandemic.
scaled for the production of mg quantities of protein (40, 41).

To assess multivalent binding, we coupled the workflow to an AlphaLISA protein-protein interaction (PPI) competition assay to enable comparison of dissociation rates of the designed proteins against either the monomeric RBD or the trimeric HexaPro SARS-CoV-2-S-glycoprotein (S6P) (42). Because multivalency largely impacts dissociation rate constants of protein-protein interactions, we reasoned that an in-solution off-rate screen could distinguish differences between mono- and multivalent binding (43). Multivalent minibinders were allowed to fully associate with the target protein, then reactions were split in two and either 100-fold molar excess of untagged competitor (to prevent reassociation) or buffer was added. MON1, MON2, and MON3 target overlapping epitopes (25), and thus mono- or multivalent versions of these minibinders were selected as competitors. The ratio of the competitor to no-competitor condition measurements were calculated to determine the fraction of the complex dissociated (44).

Paralleling previous work where trimeric binders were targeted to the sialic acid-binding site on influenza hemagglutinin (30), we first designed self-assembling homotrimeric versions of the MON1, MON2, and MON3 minibinders geometrically matched to the three RBDs in the S trimer (hereafter referred to as TRI; for example, TRI1-1 represents a homotrimer of MON1 with homotrimerization domain 1, table S1, data file S1). We designed and screened more than 100 different homotrimeric minibinders, with varied linker lengths and homotrimerization domains, using the CFPS workflow. We observed that many of the homotrimeric constructs exhibited slower dissociation rates than the corresponding monomers; much larger effects were observed with dissociation from the S trimer than monomeric RBD, consistent with multivalent binding (Fig. 1 and fig. S3). In total, we tested eleven different oligomerization domains and found that nine of these domains yielded at least one design with a linker length that improved dissociation rates on par with the top binders (fig. S3). Designs with domains four and eleven exhibited slower dissociation rates compared to their monomeric counterpart, but faster than the top designs (fig. S3E); this is likely indicative of an inability to simultaneously engage all three target epitopes or dissociation of the oligomerization domains themselves. The top binders exhibited little to no dissociation from S trimers after 7 days of incubation with competitor, indicating a likely apparent dissociation rate constant of 1x10^{-7} s\(^{-1}\) or slower (Fig. 1B). This is a marked improvement, more than four orders of magnitude for the TRI2 proteins, over the dissociation rate constants of the corresponding monomeric minibinders (fig. S4). We selected two trimeric scaffolds, the designed two ring helical bundle SB175 (domain 2) and the T4 faldon (domain 1) (45) (table S2), to proceed with based on the screening results and previous experience with these scaffolds.

Next, we generated two- and three-domain fusions of the MON1, MON2, and MON3 minibinders separated by flexible linkers (hereafter referred to as FUS; for example, FUS31-P12 represents a fusion of MON3 to MON1 separated by a 12 amino acid proline-alanine-serine (P12) linker, table S1, data file S1). We screened more than 100 different fusions using the CFPS workflow, evaluating different minibinder orderings and a range of linker compositions and lengths that span the distances between the termini of the domains when bound to the “open” and “closed” states of the RBD (Fig. 1, and fig. S3, A, B, and F) (I). We evaluated both glycine-serine (denoted as G) and proline-alanine-serine (denoted as P) linkers (46) and observed similar binding characteristics (Fig. 1 and fig. S3). We observed occasional truncation of the G linkers during expression and purification by E. coli proteases; however, this was less frequent for the P linkers than for the G linkers. FUS31 and FUS231 constructs showed slower dissociation against S6P than RBD, and exhibited slower dissociation than all monomeric minibinders tested, consistent with multivalent S6P engagement (Fig. 1). The top binders exhibited little dissociation from S6P after 7 days, indicating a likely apparent dissociation rate constant of 1x10^{-7} s\(^{-1}\) or slower, representing one order of magnitude or greater improvement over the corresponding monomeric minibinder dissociation rate constant (fig. S4). Finally, to determine the potential for low-cost purification by heat treatment, we recombinantly expressed MON1, FUS231-P12, and TRI2-2 in E. coli. The heat-treated soluble fraction was enriched with the expressed minibinder and contaminating background proteins were largely precipitated (fig. S5).

**Structural studies of minibinders in complex with SARS-CoV-2-S.**

We next determined how the designed multivalent proteins engage multiple RBDs on a single S trimer; multivalent engagement on a virion typically requires binding of a single S trimer due to the relatively sparse S distribution (47–49). For some designs, FUS31-G8 and TRI1-5-G2 for example (table S1), initial screening using negative stain EM revealed considerable cross-linking and aggregation of S trimers upon addition of the constructs (fig. S6), consistent with binding to RBDs on different S trimers. In contrast, for constructs TRI2-2, FUS231-G10, FUS231-P24 and FUS31-G10, we observed less cross-linking, consistent with multivalent engagement of a single S trimer for each minibinder. To determine the binding modes of these compounds to the S trimer and characterize the structure of the MON2 and RBD interactions at high resolution, we carried out cryogenic electron microscopy (cryoEM) characterization of these complexes (Fig. 2).

The cryoEM structures of the TRI2-2, FUS31-G10, and the FUS231-P24 constructs in complex with S6P were determined at resolutions of 2.8, 4.6, and 3.9 Å respectively (Fig. 2A to D,
that it would be possible to construct a bioluminescence res-
FUS231-P12 respectively (Fig. 3A) (Fig. 2C, fig. S7 and S9). The distance between the two RBDs in the open conformation is shorter in the FUS31-G10 than in the FUS231-P24 structure (Fig. 2C and D), suggesting that the bound minibinder holds the RBDs together, in agreement with the shorter linkers used in the former minibinder construct. In the structure, two molecules of FUS31-G10 are bound to a single S trimer with the third RBD being occupied by a second FUS31-G10 molecule. In the structure of FUS231-P24 bound to S6P, the three RBDs are participating in complex formation (Fig. 2D, fig. S7 and S10). The limited resolution in the region comprising the minibinder-bound RBDs and linkers precludes definitive assignment of minibinder identity at each binding site and relative connectivity between each minibinder module. The distances between the termini of the minibinder domains, however, is compatible with the computational design models and suggestive of engagement of either 2 (FUS31-G10) or 3 of the RBDs (FUS231-P24) in a single S trimer by the multivalent minibinders.

The structure of MON2 in complex with the S trimer has not previously been determined. Starting from the TRI2-2/S6P cryoEM data, we improved the RBD/MON2 densities using focused classification and local refinement, yielding a map at 2.9 Å resolution enabling visualization of the interactions formed by MON2 with the RBD (Fig. 2B). Superimposition of the design MON2 model to the corresponding cryoEM structure, using the RBD as reference, shows that the MON2 minibinder closely matched the design model with backbone RMSD of 1.3 Å (fig. S7E and F). Together with previous structures of MON1 and MON3 (25), these data illustrate the accuracy with which both protein scaffolds and binding interfaces can now be computationally designed.

**Multivalent minibinders enable rapid detection of SARS-CoV-2 S protein.**

Having confirmed the binding mode of the FUS231 proteins by cryoEM, we designed an S trimer sensor, reasoning that the high affinity binding of the FUS231 proteins to the S trimer could make a useful diagnostic (50). We hypothesized that it would be possible to construct a bioluminescence resonance energy transfer (BRET) sensor for S trimer, where simultaneous engagement of all three minibinders in FUS231 with the S trimer would bring the N- and C-termini close enough together to enable efficient energy transfer. Toward this goal, we designed a BRET sensor based on FUS231-P12 with teLuc and mCyRFP3 fused to the N- and C terminus of FUS231-P12 respectively (Fig. 3A) (51, 52). Upon binding of the sensor protein to a stabilized S protein with 2 proline mutations (S2P) (1, 50), we observed a 350% increase in the 590 nm:470 nm BRET ratio, which was not observed when bound to the RBD alone, and determined the limit of detection to be 11 pM S2P (Fig. 3B and C, and fig. S11). Furthermore, these results support the proposed multivalent binding mode for the FUS231 proteins.

**Multivalent minibinders bind tightly to SARS-CoV-2 variants.**

We next evaluated the resiliency of the binding of multivalent minibinders to the previously identified MON1 and MON2 escape mutants as well as mutations present in the B.1.1.7 (Alpha), B.1.351 (Beta), and P.1 (Gamma) SARS-CoV-2 VOCs. We first measured the off-rate of the best multivalent minibinders using competition AlphaLISA with TRI2-1 against a panel of mutant S glycoproteins (Fig. 4A). Multivalent minibinders were allowed to fully associate with mutant S trimers and subsequently were competed with 100-fold molar excess of untagged TRI2-1 to measure dissociation of the complex. The two-domain fusions (FUS23 and FUS31) did not show improved binding to the tested point mutants. The three-domain fusions (FUS31) retained binding to the tested mutants, indicating that they are more resistant to mutations than their monomeric counterparts, although E406W, Y453R, and the combination of K417N, E484K, and N501Y mutations (present in the B.1.351 S trimer) increased the dissociation rate more than 100-fold. Consistent with these results, we also observed increased dissociation rates for the FUS231 proteins against the B.1.351 and P.1 spikes by surface plasmon resonance (SPR) (fig. S12). The TRI1 and TRI3 homotrimers showed similar mutational tolerance in the competition experiment, with the same E406W, Y453R, and B.1.351 mutations causing increased dissociation rates. Strikingly, the TRI2 designs showed little dissociation after 24 hours against any of the tested S trimer mutants.

We subsequently screened the top multivalent minibinders for binding to mutant S trimers by an ACE2 competition enzyme-linked immunosorbent assay (ELISA), which correlates with neutralization potency (53). The minibinders were pre-incubated with the S6P variants before binding to immobilized ACE2 (Fig. 4B and fig. S13). In line with deep mutational scanning data, we observed impaired binding to the E406W, Y453R, and Y453R, and the combination of K417N, E484K, and N501Y mutations (present in the B.1.351 S trimer) increased the dissociation rate more than 100-fold. Consistent with these results, we also observed increased dissociation rates for the FUS231 proteins against the B.1.351 and P.1 spikes by surface plasmon resonance (SPR) (fig. S12). The TRI1 and TRI3 homotrimers showed similar mutational tolerance in the competition experiment, with the same E406W, Y453R, and B.1.351 mutations causing increased dissociation rates. Strikingly, the TRI2 designs showed little dissociation after 24 hours against any of the tested S trimer mutants.

We subsequently screened the top multivalent minibinders for binding to mutant S trimers by an ACE2 competition enzyme-linked immunosorbent assay (ELISA), which correlates with neutralization potency (53). The minibinders were pre-incubated with the S6P variants before binding to immobilized ACE2 (Fig. 4B and fig. S13). In line with deep mutational scanning data, we observed impaired binding to the E406W, Y453R, and Y453R, and the combination of K417N, E484K, and N501Y mutations (present in the B.1.351 S trimer) increased the dissociation rate more than 100-fold. Consistent with these results, we also observed increased dissociation rates for the FUS231 proteins against the B.1.351 and P.1 spikes by surface plasmon resonance (SPR) (fig. S12). The TRI1 and TRI3 homotrimers showed similar mutational tolerance in the competition experiment, with the same E406W, Y453R, and B.1.351 mutations causing increased dissociation rates. Strikingly, the TRI2 designs showed little dissociation after 24 hours against any of the tested S trimer mutants.
Multivalent minibinders potently neutralize circulating SARS-CoV-2 variants.

To investigate the efficacy of the multivalent minibinders for preventing viral infection, we performed neutralization assays with the inhibitors using both pseudotyped lentiviruses and authentic SARS-CoV-2 variants (Fig. 4C to F, fig. S15). Against pseudoviruses displaying S proteins corresponding to the B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 (Delta), and B.1.617.2.1 (Delta plus, AY.1) variants, all three monomeric minibinders showed reduced neutralization capacity as compared to the Wuhan-Hu-1 D614G strain; in contrast, many of the multivalent minibinders were less affected in an ACE2 overexpressing cell line (Fig. 4C and E, and fig. S15A and C). The same proteins were also evaluated against pseudoviruses containing the E406W, L452R, and Y453F mutations, which again had little impact on neutralization for most multivalent minibinders tested (fig. S15A and C). This suggests that the increase in affinity from multivalency improved neutralization breadth. The top neutralizing minibinders from this screen were tested for neutralization of a panel of authentic SARS-CoV-2 viruses including a historical WA1/2020 strain, B.1.1.7, B.1.526 (Iota), B.1.1.529 (Omicron), B.1.617.1, B.1.617.2, and B.1.617.2.1 natural isolates, and chimeric WA1/2020 strains encoding spike genes corresponding to those of the B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2, and B.1.1.529 variants. The top candidates maintained pM-range IC50 values (Fig. 4D and F, and fig. S15B and D), except for the FUS231 proteins, which did not fully neutralize the B.1.1.529 variant in the tested concentration range. The TRI2 proteins maintained potent neutralization across all tested variants, notably including the B.1.1.7, B.1.351, B.1.526, B.1.617.1, B.1.617.2, and B.1.1.529 variants. Impressively, the TRI2 proteins potently neutralized the B.1.1.529 variant whereas many clinical mAbs for the B.1.351 variant in a human organoid system.

Multivalent minibinders resist viral escape.

Given the promising data showing that multivalent minibinders can neutralize SARS-CoV-2 VOCs, we tested the multivalent minibinders for resistance against viral escape mutations in the S trimer (Fig. 5A and B) (6). Plaque assays were performed with a VSV-SARS-CoV-2 S chimera on Vero CCL-81 cells with minibinders included in the overlay to halt spread of non-resistant viruses. In positive control wells, inclusion in the overlay of 2B04, a potent neutralizing antibody targeting the RBD (6, 58–60), resulted in multiple escape mutants in each plate similar to previously reported escape mutants (Fig. 5A) (6). In contrast, for both FUS231-P12 and TRI2-2, escape mutants were not isolated in 36 replicate wells for each protein (fig. S17). These data indicate that both the FUS231-P12 and TRI2-2 proteins are more difficult to escape than 2B04. Given the known mutation rate of the VSV RNA polymerase L (61) and the number of viral particles screened, we estimated (table S5) that, for the multivalent minibinders, the screened pool of viral mutants contains a large fraction of the possible single amino acid substitutions (34% to 88%) and a small fraction of the possible double amino acid substitutions (0.4% to 9.6%) within the region of the RBD that contacts the minibinders. Taken together with the results of the single site saturation mutagenesis studies for the monovalent minibinders (fig. S1) these findings indicate that at least two or more mutations in the RBD are likely necessary to escape binding of the multivalent minibinders.

Multivalent minibinder confers protection in human ACE2-expressing transgenic mice.

To determine whether the multivalent minibinders can prevent or treat SARS-CoV-2 infection in vivo, we performed pre-exposure prophylaxis or post-exposure therapy studies in highly susceptible K18-hACE2 transgenic mice (62) with TRI2 multivalent minibinders, which retained the most consistent binding to all S trimer variants tested. For prophylaxis, a single 50 μg dose (about 2.5 mg/kg) of TRI2-1 or TRI2-2 was administered directly to the nasal cavity (intranasal administration) one day prior to inoculation with 10^7 focus forming units (FFU) of the indicated SARS-CoV-2 VOCs (Fig. 6A). In all cases, intranasal administration of TRI2-1 or TRI2-2 protected mice against SARS-CoV-2-induced weight loss (Fig. 6B). At 6 days post infection, viral burden in tissues was reduced in almost all primary (lung and nasal wash) and secondary sites (heart, spleen, brain) of viral replication in TRI2-1 and TRI2-2 treated animals (Fig. 6C). To determine the therapeutic potential of TRI2-2, we inoculated K18-hACE2 mice with 10^5 FFU of Wash-B.1.351 or B.1.617.2 and one day later, administered a single 50 μg dose of minibinder intranasally (Fig. 6D). Treatment with TRI2-2 protected against weight.
loss and reduced viral burden in all tissues except nasal washes (Wash-B.1.351) or the spleen (B.1.617.2) (Fig. 6E and F). TRI2-2 therapy at D+1 reduced infectious virus titers in the lungs of Wash-B.1.351- and B.1.617.2-infected mice (fig. S18). We determined the pharmacokinetics of TRI2-2 after intranasal administration by quantitative competition ELISA. Substantial concentrations of TRI2-2 were detected in the lung lysate and serum 48 hours after administration (fig. S19) but was too low for confident quantification in nasal turbinates after the first time point and for confident quantification in nasal washes at all time points. These results indicate that intranasal administration of TRI2-1 or TRI2-2 confer protection against SARS-CoV-2 infection as both pre-exposure prophylaxis and post-exposure therapy in a stringent model of disease.

DISCUSSION

Both strategies for generating multivalent S protein binders from miniproteins, self-assembling homotrimer (TRI) and multi-domain fusions (FUS), yielded designs with improved affinity, neutralization of current and historical VOCs, and resistance to escape mutants over their monovalent counterparts (25, 26). The TRI2 proteins maintained the strongest binding across all S trimer variants tested, likely because MON2 is an ACE2 mimic, similar to the recently reported S2K146 mAb (15, 24). This combination of trivalency and receptor mimicry could be a useful general approach for combating viral escape and antigenic drift (15, 24, 36, 53, 63, 64).

The designs also have potential advantages as therapeutics over ACE2 receptor traps and mAbs. When compared to receptor traps (55, 65–67), TRI2-2 has a low risk of eliciting host-directed anti ACE2 responses due to low sequence similarity between MON2 and ACE2. On a per mass basis, the TRI2 proteins are more potent neutralizers than all currently authorized mAbs for the treatment of COVID-19 (15, 16), and, unlike most clinical mAbs, they maintain activity against Omicron. The multivalent minibinders are amenable to large-scale production in microorganisms like E. coli, making them more cost-effective to manufacture than mAbs (8). Furthermore, their small size and stability may enable direct nebulization into the human upper respiratory tract (3, 68–70), a strategy that could increase accessibility for patients over the typical intravenous or subcutaneous routes used for administering neutralizing mAbs.

The high potency of the multivalent constructs, in particular TRI2-2 against Omicron, Delta, and the other tested VOCs, makes them promising candidate SARS-CoV-2 therapeutics, and they are currently undergoing further preclinical development and investigational new drug (IND) enabling studies. These efforts will address limitations in our current study. First, anti-drug antibodies are a concern with non-human proteins and, although MON1 and other minibinders (26, 77) elicit little or no immune response, additional studies are required to determine the immunogenicity of the multivalent constructs. Second, it will be important to assess the pharmacokinetics following different modes of administration; in humans, it may be necessary to distribute the compound deeper into the respiratory system for post infection efficacy. Third, as with any new drug candidate going through the drug development pipeline, it will be necessary to assess its stability as well as its potency and toxicity after prolonged administration.

In summary, our integration of structure-guided computational protein design, cell-free DNA assembly, cell-free expression, and a competition-based off-rate screen enabled the rapid design and optimization of S trimer-engaging multivalent minibinders. Scaling cell-free expression to manufacture mg quantities of endotoxin-free protein for cell-based neutralization assays further reduced the time required to evaluate lead molecules. The developed pipeline has direct relevance to diagnostics as well; the FUS231-based BRET sensor is easy to use, fast, and has the potential to be less expensive than state-of-the-art lateral flow assay-based antigen tests (72, 73). Our integrated computational and experimental pipeline should enable the rapid generation of potent protein-based medical countermeasures and diagnostic reagents against newly emerging pathogens.

MATERIALS AND METHODS

Study design

The objective of this study was to design and evaluate multivalent minibinders that neutralize SARS-CoV-2 variants containing mutations within the RBD. At the outset, we hypothesized that multivalency would overcome mutations that reduce binding for individual monomeric minibinders. Designed proteins were evaluated in controlled laboratory experiments, first using biophysical methods with purified proteins (AlphaLISA and ELISA competition assays) followed by in vitro methods requiring cell culture (pseudovirus and authentic virus neutralization assays). The top candidates from neutralization assays were screened by electron microscopy for cross-linking multiple S trimers and the candidates that were found to minimally cross-link S trimers were subjected to structural analysis by cryoEM. The most promising proteins were evaluated in vivo in mice. In all studies where cell lines were used, the cell line is noted in the corresponding materials and methods section. The total number and type of experimental replicates is noted in each figure legend. Details on the in vivo mouse study compliance with best practices can be found in the corresponding materials and methods section. No sample-size calculations were performed to power each in vivo study. Instead, sample sizes and study endpoints were determined based on previous in vivo virus challenge experiments. For all other experiments, sample size was selected based on previous literature and previous
experience. In the animal studies, mice were randomly assigned to the control and treatment groups. Animal caretakers and researchers were not blinded to the study groups or during the assessment of the outcomes. Data that underlie the results reported in this article can be found in data file S2, data file S3, and in the deposited data listed in the data and materials availability statement.

Statistical analysis

Statistical significance was determined by a P value < 0.05 using GraphPad Prism 9 software. Only non-parametric tests were used throughout this article. Analysis of mouse weight changes was performed using a two-way analysis of variance (ANOVA) with Sidak's post-test for multiple comparisons. Statistical analysis of viral load between two groups was performed using either a Kruskal-Wallis test with Dunn's post-hoc analysis for multiple comparisons or a two-tailed Mann-Whitney test as noted in the corresponding figure captions.

SUPPLEMENTARY MATERIALS

www.science.org/doi/10.1126/scitranslmed.abn1252

Materials and Methods

Figs. S1 to S19

MDAR Reproducibility Checklist

Data files S1 to S3

REFERENCES AND NOTES


74


First release: 12 April 2022
Institute for Protein Design (to D.B. and H.-W.Y.); Eric and Wendy Schmidt by recommendation of the Schmidt Futures (to H.-W.Y., L.M., L.K, R.R., and I.G.); the Bill & Melinda Gates Foundation (OPP1156526 to D.V. and D.B.; INV-004549 to J.D.B.); The Open Philanthropy Project Improving Protein Design Fund (to D.B. and S.E.B.); a Career Award at the Scientific Interface Grant from the Burroughs Wellcome Fund (to S.E.B.); European Commission MSCA CC-LEGO 792305 (to A.L.); the Wu Tsai Translational Investigator Fund at the Institute for Protein Design (to G.U.); the National Institute of General Medical Sciences (RO1GM120553 to D.V.) (NIHPO1GM081619, RO1GM097372, RO1GM083867 and the NHLBI Progenitor Cell Biology Consortium U10HL099997; U10HL099993 to H.R.B.); the National Institute of Allergy and Infectious Diseases (DPIA105816 to D.V.; HSNS272201700595C to D.V., L.S., and D.B.; R37 AI059371 to S.P.J.W.; RO1 AI045486 to B.R.L. and N.P.); the National Institute of Diabetes and Digestive and Kidney Diseases (RO1DK137194, RO1DK130386, and U01DK127553 to B.S.F.; F33DK130550 to L.H.); the National Center for Advancing Translational Sciences (UG3TR002158 to J.H. and B.S.F.); the United World Antiviral Research Network -UWARN- one of the Centers Researching Emerging Infectious Diseases “CREIDs”; U01 AI51698-01 (to D.B., L.S., M.G., and H.-W.Y.); RO1 AI57555 to M.S.D.); a Pew Biomedical Scholars Award (to D.V.); Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (to D.V.); Fast Grants (to D.V. and A.A.); A Helen Hay Whitney Foundation postdoctoral fellowship (to J.B.C); T50 Training Grant (to Y.T.Z.); an HHMI Fellowship from the Damon Runyon Cancer Research Foundation (to T.N.S).; Howard Hughes Medical Institute (to J.D.B., D.V., and D.B.); the National Institute of Health Cellular and Molecular Biology Training Grant (T32GM007270 to A.A.); the University of Washington Arnold and Mabel Beckman cryoEM center and the National Institute of Health grant S1000032290 to D.V.). This project has also been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HSNS272201700595C (to D.V., L.S., and D.B.). J.D.B. and D.B. developed the cell-free DNA assembly and protein expression workflow, developed the off-rate multivalency screening assay, assisted in the optimization of the minibinders and selection of final candidates, manufactured the multivalent minibinders for screening and cell-based assays, screened the minibinders and multivalent minibinders in the off-rate assay and analyzed the results, and prepared the article for submission. J.B.C. performed authentic virus neutralization assays and data analysis; assisted in minibinder prioritization and selection of final candidates; performed mouse in vivo experiments, tissue processing, virus quantification, and data analysis. J.Y.P. performed cryoEM experiments and analysis. L.Cao optimized the de novo minibinders and originated the multivalent project. L.Cao and A.C.H. originated the multi-domain fusions. L.Cao, L.S., and A.C.H. designed the multi-domain fusions. K.W. originated and designed the homotrimers. K.W. and S.E.B. optimized the homotrimers. A.C.W. designed and piloted the minibinder-S6P-ACE2 competition assay and assisted with data analysis; organized reagents and prioritized and planned experiments; performed pseudovirus neutralization assays and data analysis and assisted in minibinder prioritization and selection of final candidates. Z.L. performed and analyzed the chimeric virus escape experiments. J.E.B. performed and analyzed the competition ELISA experiments, with the assistance of A.A.M. performed the biochemical assays for pharmacokinetic analyses. H.W.Y., with the assistance of N.P., performed and analyzed the sensing experiments. S.S., L.H., Y.T.Z., and T.-Y.H. performed and analyzed the kidney organoid experiments. T.N.S., with the assistance of A.A., performed and analyzed the RBD deep mutational scanning experiments. I.G. and L.K. assisted in the optimization of minibinders. R.R. and L.Carter expressed multivalent minibinders for animal studies and expressed S6P variants. R.R. performed and analyzed heat purification experiments. L.B.G., W.L.M., and C.A.T., performed and analyzed BLI and SPR experiments. B.V. and A.K. assisted with expression and purification of minibinders and with the off-rate screening assay. L.A.V., R.E.C., B.Y., A.L.B., and N.M.K. assisted with authentic virus neutralization studies and mouse studies. S.E.B. designed SB75. A.L., N.E., and G.U. assisted in the design of the homotrimers. A.L. assisted in the computational method development for homotrimers. N.E., A.L., and G.U. assisted in linker and oligomer selection. C.M.C. assisted with the expression and purification of homotrimers. M.J.N. prepared the Delta variant pseudovirus for pseudovirus neutralization experiments. M.G., B.S.F., and H.R.B. were involved with the conceptualization and administration of the kidney organoid experiments. J.D.B. was involved in the conceptualization and administration of the deep mutational scanning experiments. S.P.J.W. was involved in the conceptualization and administration of the VSV escape experiments. M.S.D. was involved in the conceptualization and administration of the authentic virus neutralization experiments and mouse studies. D.V. was involved in the conceptualization and administration of the cryoEM competition ELISA, and pseudovirus neutralization experiments. M.C.J. was involved in the conceptualization and administration of the AlphaLISA and CFPS experiments. L.S. and D.B. were involved in the conceptualization and administration of the computational protein design. A.C.H., J.B.C., L.Cao, K.W., A.C.W., L.Carter, M.S.D., D.V., M.C.J., and D.B. coordinated the research. A.C.H., J.B.C., Y.J.P., L.Cao, A.C.W., K.W., J.E.B., M.S.D., R.R., S.E.B., L.S., H.W.Y., D.V., M.C.J., and D.B. wrote and edited the article. All authors discussed the results and commented on the article. Competing Interests: Each contributor attests that they have no competing interests relating to the subject contribution, except as disclosed. A.C.H., L.Cao, I.G., J.B.C., L.M., L.K., L.Carter, K.W., G.U., J.B.C., N.E., A.C.W., B.V., R.R., Y.J.P., H.W.Y., L.S., D.V., M.D., M.C.J. and D.B. are co-inventors on a patent application that incorporate discoveries described in this article (Application #: PCT/US2021/034069, Title: SARS-CoV-2 inhibitors), D.B. and H.W.Y. are co-inventors on a patent application describing the S protein sensors described in this article (Application #: 63/216,891, Title: Multivalent SARS-CoV-2 Spike Protein Biosensor); Z.L. and S.P.J.W. are co-inventors on a patent application covering the use of VSV-SARS-CoV-2 as a vaccine vector and screening tool (Application #: PCT/US2021/027275, Title: SARS-CoV-2 Vaccines and High Throughput Screening Assays Based on Vesicular Stomatitis Virus Vectors). B.S.F. and L.H. are inventors on patent applications related to kidney organoid differentiation and application (Application #: US2021220632A1, Title: High-Throughput Automation of Organoids for Identifying Therapeutic Strategies; Application #: US20183546082, Title: Three-dimensional differentiation of epithelial spheroids to kidney organoids models stage-specific epithelial physiology, morphogenesis, and disease). J.D.B. may receive a share of IP revenue as an inventor on a Fred Hutchinson Cancer Research Center-optioned technology patent (Application #: WO2020064948, Title: Cell-Stored Barcoded Deep Mutational Scanning Libraries and Uses of the Same) related to deep mutational scanning of viral proteins. D.B. is a cofounder of Neoleukin Therapeutics. The Diamond laboratory has received unrelated sponsored research support from Moderna, Vir Biotechnology, and Emergent BioSolutions. The Veesler laboratory received an unrelated sponsored research agreement from Vir Biotechnology, AbbVie, and SAB, Therapeutics. A.C.H. has consulted for SwiftScale Biologics, Stemloop, Inc., Design Pharmaceuticals, and Pearl Bio. The interests of M.C.J. are reviewed and managed by Northwestern University in accordance with their conflict-of-interest policies. L.G., W.M. and C.T. are current employees of Amgen and own Amgen stock. Z.L. and S.P.J.W. received unrelated sponsored research agreements from Vir Biotechnology, AbbVie, and SAB Therapeutics. A.C.H. has consulted for SwiftScale Biologics and L.E.K. Consulting. M.S.D. is a consultant for Inbios, Vir Biotechnology, and Carnival Corporation and is on the Scientific Advisory Board of Moderna and Immunome. H.R.B. is a Scientific Advisor of Curibio. J.D.B. consults for Moderna on viral evolution and epidemiology and Flagship Labs 77 on deep mutational scanning. All other authors declare no competing interests. Data and Materials Availability: All data associated with this study are in the paper or supplementary materials. Structural models and density maps have been deposited in the Protein Data Bank (PDB) (SARS-CoV-2/TRI2-2: 7UHC and SARS-CoV-2/TRI2-2 (local refinement): 7UHB) and Electron Microscopy Data Bank (EMDB) (SARS-CoV-2/TRI2-2: EMD-26512, SARS-CoV-2/TRI2-2 (local refinement): EMD-26511, SARS-CoV-2/FUS31-G10 (2RD: open): EMD-26509, SARS-CoV-2/FUS31-G10 (3RD: open): EMD-26510, SARS-CoV-2/FUS231-P24 (2RD: open): EMD-26507, and SARS-CoV-

Requests for reagents (antibodies, viruses, and other proteins) should be directed to the corresponding authors and will be made available after completion of a Materials Transfer Agreement with the University of Washington. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/

This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using this material.

Submitted 5 November 2021
Accepted 5 April 2022
Published First Release 12 April 2022
10.1126/scitranslmed.abn1252
Fig. 1. Multivalent minibinders exhibit very slow dissociation rates upon binding to the prefusion SARS-CoV-2-S glycoprotein trimer. Dissociation of the minibinder construct was monitored by competition with 100-fold molar excess of untagged MON1 using AlphaLISA (Mean ± SEM, n = 3 technical replicates from a single experiment). (A) Dissociation was measured for indicated minibinder constructs complexed with the receptor-binding domain of SARS-CoV-2 (RBD). (B) Dissociation was measured for the indicated minibinder constructs complexed with the S trimer (S6P).
Fig. 2. CryoEM structures of multivalent minibinders in complex with the SARS-CoV-2 S6P glycoprotein. TRI2-2 is a homotrimer of MON2 using the SB175 homotrimerization domain, FUS31-G10 is a fusion of MON3 to MON1 with a 10 amino acid glycine-serine linker, FUS213-P24 is a fusion of MON2 to MON1 to MON 3 with a 24 amino acid proline-alanine-serine linker, and FUS213-G10 is a fusion of MON2 to MON1 to MON 3 with a 10 amino acid glycine-serine linker. (A) A CryoEM map of TRI2-2 in complex with the S6P in two orthogonal orientations is shown. (B) A zoomed-in view of the TRI2-2 and RBD complex was obtained using focused 3D classification and local refinement. The RBD and MON2 built in the 2.9 Å resolution cryoEM map are shown in yellow and blue, respectively. (C) A cryoEM map of FUS31-G10 bound to S6P is shown. (D) A cryoEM map of FUS213-P24 bound to S6P is shown. (E) A negative-stain EM map of FUS213-G10 in complex with S6P is shown. S and minibinder models were docked in the whole map by rigid body fitting for visualization. In all panels, the EM density is shown as a transparent gray surface, S protomers (PDB 7JZL) are rendered in yellow, cyan, and pink and minibinders (PDB 7JZU, 7JZM, and MON2 structure was determined in this study) are shown in orange.
Fig. 3. FUS231-P12 enables detection of SARS-CoV-2 S trimer through BRET. (A) A schematic representation of the BRET sensor, teluc-FUS231-P12-mCyRFP3, to detect S trimer is shown. (B) Luminescence emission spectra and image of the BRET sensor (100 pM) in the presence (orange trace, 100 pM) and absence (blue trace) of S2P are shown. Emission color change was observed using a mobile phone camera (inset top right). RLU, relative light units. (C) Titration of S2P with 100 pM sensor protein is shown. LOD indicates limit of detection. R² value is shown on the graph. Data are presented as mean ± SEM with n = 3 technical replicates from a single experiment.
**Fig. 4. Multivalency enhances both the breadth and potency of neutralization against SARS-CoV-2 variants by minibinders.** (A) Dissociation of minibinder constructs from S6P variants after 24 hours was measured by competition with untagged TRI2-1 using AlphaLISA. Means are shown with n = 3 technical replicates from a single experiment. Cells containing an X indicate insufficient signal in the absence of a competitor to quantify the fraction of protein bound. (B) Competition of minibinder constructs with ACE2 for binding S6P were measured by ELISA. Data are presented as mean values for n = 2 technical replicates representative of two independent experiments. (C) Neutralization of SARS-CoV-2 pseudovirus variants by minibinder constructs are shown. Data are presented as means of n = 2 technical replicates representative of two independent experiments. (D) Neutralization of authentic SARS-CoV-2 by minibinder constructs was measured. Data are presented as mean ± SEM with n = 4 technical replicates from two independent experiments for all but B.1.1.529, where n = 8 technical replicates from four independent experiments. (E) Summary of neutralization potencies of multivalent minibinder constructs against SARS-CoV-2 pseudovirus variants are shown. N/A indicates an IC_{50} value above the tested concentration range and an IC_{50} greater than 50,000 pM. (F) Summary of neutralization potencies of multivalent minibinder constructs against authentic SARS-CoV-2 variants are shown. N/A indicates an IC_{50} value above the tested concentration range and an IC_{50} greater than 30,000 pM. NT indicates not tested. (G) Replicating authentic B.1.351 virus in the presence of minibinder constructs (0.3 μM) was quantified in human kidney organoids. Data are presented as mean ± SEM, n = 4 biological replicates with 2 to 3 technical replicates per experiment. Data were compared to the no inhibitor control by a Kruskal-Wallis test with Dunn’s post-hoc analysis; ** P < 0.01, *** P < 0.001. Dashed line indicates lower limit of detection of plaque assay. (H) Relative gene expression of SARS-CoV-2 envelope protein (SARS-CoV2-E) was measured in kidney organoids post viral infection with and without multivalent minibinders (0.3 μM). Data were presented as mean ± SEM of n = 4 biological replicates with 2 to 3 technical replicates per experiment. Data were compared to the no inhibitor control by a Kruskal-Wallis test with Dunn’s post-hoc analysis; * P < 0.05, *** P < 0.001.
Fig. 5. Top multivalent minibinder candidates are resistant to viral escape. 
(A) Plaque assays were performed to isolate VSV-SARS-CoV-2 S chimera virus escape mutants against a control neutralizing antibody (2B04) and the FUS231-P12 and TRI2-2 multivalent minibinders. For each inhibitor tested, Vero CCL-81 cells were incubated with VSV-SARS-CoV-2 S chimera virus for one hour, followed by addition of the inhibitor protein at a fully neutralizing concentration and further incubation to allow for replication and spread of resistant viruses. Thirty-six independent selections were carried out for each minibinder compound in a single experiment; representative examples are shown in the images. Small plaques are indicative of inhibited viral spreading and large plaques, highlighted by black arrows, are indicative of viral escape mutants spreading. (B) A summary of the results of the viral escape screen are shown. NAb, neutralizing antibody.
Fig. 6. Top multivalent minibinder candidates protect mice from SARS-CoV-2 challenge. (A) K18-hACE2-transgenic mice (n = 6 from two independent experiments) were dosed with 50 μg of the indicated minibinder by intranasal (i.n.) administration (50 μl total) 24 hours prior (D-1) to infection with 10^3 focus forming units (FFU) of SARS-CoV-2 variants B.1.1.7, Wash-B.1.351, or Wash-P.1 i.n. on Day 0. (B) Daily weight change following inoculation was measured. Data are presented as mean ± SEM. Data were analyzed by a two-way ANOVA with Sidak’s post-test; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 as compared to the control minibinder. (C) At 6 days post infection (dpi), animals (n = 6 from two independent experiments) were euthanized and analyzed for SARS-CoV-2 viral RNA by RT-qPCR in the lung, heart, spleen, brain, and nasal wash. Horizontal bars indicate median; dashed lines represent the limit of detection. Data were analyzed by a Kruskal-Wallis test with Dunn’s post-hoc analysis; ns, not significant, * P < 0.05, ** P < 0.01, *** P < 0.001. (D) K18-hACE2-transgenic mice (n = 6 from two independent experiments) were dosed with 50 μg of the indicated minibinder by i.n. administration (50 μl total) 24 hours after (D+1) infection with 10^3 FFU of the SARS-CoV-2 Wash-B.1.351 or B.1.617.2 variant on Day 0. (E) Daily weight change following inoculation was measured. Data are presented as mean ± SEM. Data were analyzed by two-way ANOVA with Sidak’s post-test; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. (F) At 6 dpi (B.1.351) or 7 dpi (B.1.617.2), animals (n = 6 from two independent experiments) were euthanized and analyzed for SARS-CoV-2 viral RNA by RT-qPCR in the lung, heart, spleen, brain, and nasal wash. Horizontal bars indicate median; dashed lines represent the limit of detection. Data were analyzed by a two-tailed Mann-Whitney test; ns, not significant, * P < 0.05, ** P < 0.01.
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice


Sci. Transl. Med., Ahead of Print • DOI: 10.1126/scitranslmed.abn1252

View the article online
https://www.science.org/doi/10.1126/scitranslmed.abn1252
Permissions
https://www.science.org/help/reprints-and-permissions